181867-19-6

Basic information

• Product Name: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)
• Synonyms: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI);1-Methyl-1H-benzo[d]imidazole-6-carbaldehyde;1H-Benzimidazole-6-carboxaldehyde, 1-methyl-;1-Methyl-1H-1,3-benzodiazole-6-carbaldehyde;3-methylbenzimidazole-5-carbaldehyde
• CAS NO: 181867-19-6
• Molecular Formula: C₉H₈N₂O
• Molecular Weight: 160.17262
• Product Categories: BENZIMIDAZOLE;ALDEHYDE
• Mol File: 181867-19-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 336.9 °C at 760 mmHg
• Flash Point: 157.5 °C
• Appearance: /
• Density: 1.21 g/cm³
• Vapor Pressure: 0.000109mmHg at 25°C
• Refractive Index: 1.622
• PKA: 4.41±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)(181867-19-6)
• EPA Substance Registry System: 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI)(181867-19-6)

Safety Data

• Hazardous Substances Data: 181867-19-6(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI) is a chemical compound with the molecular formula C9H8N2O. It is a yellowish solid substance that is commonly used in the pharmaceutical industry for the synthesis of various drugs. 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI) has a benzimidazole ring structure with a carboxaldehyde functional group and a methyl substituent at the 1-position. It possesses potential biological activities and is being investigated for various therapeutic applications, particularly in the development of anticancer and antiviral drugs. Additionally, it is also used as a building block in organic synthesis for the preparation of other chemical compounds. Due to its versatile properties and applications, 1H-Benzimidazole-6-carboxaldehyde, 1-methyl- (9CI) is an important and valuable chemical in both the research and industrial sectors.

InChI:InChI=1/C9H8N2O/c1-11-6-10-8-3-2-7(5-12)4-9(8)11/h2-6H,1H3

Upstream product

• 7790-28-5 sodium periodate 
• 813449-02-4 1-methyl-6-vinyl-benzimidazole 
• 68-12-2 N,N-dimethyl-formamide 
• 53484-16-5 6-bromo-1-methyl-1H-benzo[d]imidazole 
• 177476-75-4 3-methoxy-4-nitrobenzoinitrile 
• 92241-87-7 3-methoxy-4-nitrobenzamide 
• 64910-48-1 3-N-(methylamino)-4-nitrobenzonitrile 
• 64910-49-2 4-amino-3-(methylamino)benzonitrile 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 106429-29-2 5-(hydroxymethyl)-benzimidazole 
• 15788-16-6 5-benzimidazolecarboxylic acid 
• 58442-17-4 1H-benzo[d]imidazole-5-carbaldehyde 
• 74-88-4 methyl iodide 
• 53484-14-3 3-methyl-3H-benzoimidazole-5-carbonitrile 

Relevant articles and documents

NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES

Provided are novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, provided are the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, prepa

IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE

The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.